# Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria

> **NCT02110784** · PHASE2 · TERMINATED · sponsor: **Alfasigma S.p.A.** · enrollment: 27 (actual)

## Conditions studied

- Malaria, Vivax

## Interventions

- **DRUG:** Eurartesim tablets

## Key facts

- **NCT ID:** NCT02110784
- **Lead sponsor:** Alfasigma S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06-18
- **Primary completion:** 2016-11-23
- **Final completion:** 2017-04-30
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Low recruitment
- **Last updated:** 2018-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02110784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02110784, "Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02110784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*